Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
4D Molecular Therapeutics Inc (4DMT) is a clinical-stage biopharmaceutical company focused on developing genetic medicines to treat large-market diseases. The company’s therapy areas include ophthalmology, pulmonology, and cardiology. It utilizes the proprietary therapeutic vector evolution platform to create customised gene delivery vectors for targeted therapeutic applications. 4DMT's major products include clinical-stage candidates such as the 4D-150 for the treatment of wet AMD and DME through late-stage studies and 4D-710 for the treatment of cystic fibrosis. Its other pipeline products include 4D-175 for the treatment of geographic atrophy, 4D-725 for the treatment of alpha-1 antitrypsin deficiency, and 4D-310 for the treatment of Fabry disease cardiomyopathy. The company operates its research, development, and manufacturing facility in the US. 4DMT is headquartered in Emeryville, California, the US.
Headquarters
United States of America
Address
5858 Horton Street #455, Emeryville, California, 94608
Website
www.4dmoleculartherapeutics.com
Telephone
1 510 5052680
No of Employees
196
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FDMT (NASD)
Revenue (2024)
$85.2M
230194.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
12.9%
(2024 vs 2023)
Market Cap*
$609.0M
Net Profit Margin (2024)
XYZ
100.0%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| Retina: |
| Wet AMD and Diabetic Retinopathy (4D-150) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company entered into a licensing agreement with Otsuka Pharmaceutical, granting development and commercialization rights for its gene therapy candidate 4D-150 in Asia and Oceania. |
| 2025 | Regulatory Approval | In May, the company received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration for its 4D-150 for the treatment of diabetic macular edema (DME). |
| 2024 | Regulatory Approval | In June, the company received regulatory approval from the US FDA for an IND application for 4D-175 genetic medicine for the treatment of geographic atrophy. |
Competitor Comparison
| Key Parameters | 4D Molecular Therapeutics Inc | Roche Holding AG | AbbVie Inc | Takeda Pharmaceutical Co Ltd | Regeneron Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | Japan | United States of America |
| City | Emeryville | Basel | North Chicago | Chuo-Ku | Tarrytown |
| State/Province | California | Basel-Stadt | Illinois | Tokyo | New York |
| No. of Employees | 196 | 112,774 | 57,000 | 47,029 | 15,410 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John F. Milligan, Ph.D. | Chairman | Executive Board | 2020 | 65 |
| David Kirn, M.D. | Chief Executive Officer; Director | Executive Board | 2013 | 64 |
| Kristian Humer | Chief Financial Officer | Senior Management | 2025 | 51 |
| Julie Clark, M.D. | Chief Medical Officer | Senior Management | 2025 | - |
| Scott Bizily, Ph.D. | Chief Legal and Human Resources Officer; Secretary | Senior Management | 2022 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer